Filtered By:
Condition: Renal Failure
Nutrition: Vitamins

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Anxiety in Patients With Acute Ischemic Stroke: Risk Factors and Effects on Functional Status
Conclusion: Depressive symptoms are the major correlates of PSA while more severe PSA is associated with poorer ADL and health-related QOL. Acute lesions involving CHWM may correlate with PSA in ischemic stroke patients with mild-to-moderate neurologic deficits, supporting a lesion-location hypothesis in PSA.IntroductionAnxiety is prevalent after stroke and occurs in about one-quarter of stroke survivors (1, 2). Poststroke anxiety (PSA) may have a negative impact on quality of life (QOL) of stroke survivors, affecting their rehabilitation (3). Furthermore, one prospective study found that severe anxiety symptoms were assoc...
Source: Frontiers in Psychiatry - April 16, 2019 Category: Psychiatry Source Type: research

Non-vitamin K oral anticoagulant drugs for stroke prevention in patients with atrial fibrillation and chronic kidney disease.
Abstract Atrial fibrillation (AF) and chronic kidney disease (CKD) are disorders with increasing prevalence. The presence of CKD increases the risk of incident AF and vice versa, and the presence of AF may accelerate CKD progression. Nearly a third of patients with established CKD also have AF, whilst half of AF patients may have some degree of renal dysfunction. Both AF and CKD are associated with increased cardiovascular morbidity and mortality, including significantly increased risk of stroke or systemic embolism. Oral anticoagulant therapy (OAC), either with vitamin K antagonists or with non-vitamin K oral ant...
Source: Current Medicinal Chemistry - February 10, 2016 Category: Chemistry Authors: Potpara TS, Jokic V, Dagres N, Larsen TB, Lane DA, Hindricks G, Lip GY Tags: Curr Med Chem Source Type: research

Major Bleeding and Hemorrhagic Stroke with Direct Oral Anticoagulants in Patients with Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.
CONCLUSIONS: As a class, DOACs are associated with reduced risk for hemorrhagic stroke in patients with RF compared to VKA. However, DOACs may differ from each other in their relative risk for major bleeding in patients with eCrCL <50mL/min. PMID: 26836922 [PubMed - as supplied by publisher]
Source: Chest - January 18, 2016 Category: Respiratory Medicine Authors: Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I Tags: Chest Source Type: research

Is left atrial appendage closure useful for stroke prevention in atrial fibrillation patients with renal failure?
With great interest we read the article by Kefer et al. about the impact of chronic kidney disease on left atrial appendage (LAA) occlusion with the ACP device for stroke prevention in patients with atrial fibrillation (AF) [1]. We agree with the authors that stroke prevention in AF patients with chronic kidney disease is a problem due to increased bleeding complications during oral anticoagulant therapy with vitamin K antagonists. Furthermore, the use of non-vitamin K-antagonist oral anticoagulants (NOACs) is dangerous or contraindicated in these patients.
Source: International Journal of Cardiology - April 14, 2016 Category: Cardiology Authors: Claudia Stöllberger, Josef Finsterer, Birke Schneider Source Type: research

Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention
New oral anticoagulants (NOAs), like the thrombin-inhibitor dabigatran etexilate or the factor Xa-inhibitor rivaroxaban showed similar efficacy as the vitamin-K-antagonist (VKA) warfarin for stroke prevention in patients with atrial fibrillation (AF) . One of the advantages of the NOAs, compared with VKAs, should be the lack of the necessity for laboratory monitoring and its lower rate of drug- and food interactions. The serum concentration of NOAs, however, is influenced by renal function. Furthermore, NOA-absorption is dependent on the intestinal P-glycoprotein (P-gp)-system, and P-gp activity is influenced by several dr...
Source: International Journal of Cardiology - February 11, 2013 Category: Cardiology Authors: Florian Höllerl, Claudia Stöllberger, Josef Finsterer Tags: Letters to the Editor Source Type: research

Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study
Conclusions: Our results show that patients with a history of ICH carry a significant risk of recurrent ICH when treated with VKA anticoagulation. The risk is also present, though to a lower degree, in patients with previous posttraumatic events. All patients with a history of ICH require a careful evaluation of their thromboembolic risk to estimate the net clinical benefit of (re)starting anticoagulation with VKAs.
Source: Neurology - March 24, 2014 Category: Neurology Authors: Poli, D., Antonucci, E., Dentali, F., Erba, N., Testa, S., Tiraferri, E., Palareti, G., On behalf of the Italian Federation of Anticoagulation Clinics (FCSA) Tags: Stroke prevention, Intracerebral hemorrhage ARTICLE Source Type: research

Relationship between Chronic Kidney Disease, Time-in-Therapeutic Range, and Adverse Outcomes in Atrial Fibrillation: A post hoc Analysis from the AMADEUS Trial
Conclusion: Deteriorated renal function has a small negative impact on the quality of anticoagulation control with VKA which is linked to poor outcomes in AF. However, moderate renal failure itself was an independent risk factor for increased risk of stroke, major bleeding, and all-cause mortality amongst patients with AF.Cerebrovasc Dis
Source: Cerebrovascular Diseases - July 28, 2021 Category: Neurology Source Type: research

Individualized antithrombotic therapy.
Conclusion: An extensive therapeutic arsenal to interfere with clot formation requires an individualized approach considering the disease condition and co-morbidities of the patient, the anticoagulants' and patientcharacteristics. This review builds on and extens previous publications of the authors on this topic. PMID: 25597592 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 19, 2015 Category: Hematology Authors: Lüscher TF, Steffel J Tags: Hamostaseologie Source Type: research

Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease.
CONCLUSIONS: In cases of stroke, renal failure and inadequate anticoagulation it is not useful to change from vitamin-K-antagonists to "low dose" DOAC. Diligent investigations for the cause of INR-instability and continuation of vitamin-K-antagonist therapy seem to be more effective and safer since there is the opportunity of monitoring therapy and to avoid under- as well as over-dosage. PMID: 26048606 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - May 1, 2015 Category: Neurology Authors: Stöllberger C, Finsterer J Tags: Neurol Neurochir Pol Source Type: research

Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines.
Authors: Młodawska E, Tomaszuk-Kazberuk A, Łopatowska P, Musiał WJ, Małyszko J Abstract Atrial fibrillation (AF) frequently occurs in patients with chronic kidney disease (CKD), and the rate reaches even 30% in patients with end-stage renal disease (ESRD). Patients with AF and CKD have a significantly higher risk of thrombotic complications, particularly ischemic stroke, and at the same time, a higher bleeding risk (proportionally to the grade of renal failure). In addition, AF and CKD share a number of comorbidities and risk factors, which results in increased mortality rates. Moreover, disturbances in hemosta...
Source: Polskie Archiwum Medycyny Wewnetrznej - June 2, 2016 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Vitamin K and non-vitamin K antagonists oral anticoagulants for non-valvular atrial fibrillation in real-life.
CONCLUSION: Patients given rivaroxaban and apixaban in clinical practice have a higher thrombotic and hemorrhagic risk in comparison with patients given dabigatran or VKAs. A considerable proportion of patients receive reduced doses of NOACs. PMID: 27394924 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - July 5, 2016 Category: Internal Medicine Authors: Giustozzi M, Vedovati MC, Verdecchia P, Pierpaoli L, Verso M, Conti S, Cianella F, Marchesini E, Filippucci E, Agnelli G, Becattini C Tags: Eur J Intern Med Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review
AbstractPurpose of ReviewWe investigated the risk profiles of patients using direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to estimate the importance of potential (measured or unmeasured) confounding factors in analyses comparing these drugs. We searched MEDLINE and EMBASE (2008 –2018) for relevant studies and extracted information on age, sex, comorbidity, Charlson comorbidity index, HAS-BLED score (assessing risk of bleeding) and CHA2DS2-VASc score (assessing risk of stroke).Recent FindingsOverall, 66 studies with 2,808,757 patients were included. Most patients were from Fr...
Source: Current Epidemiology Reports - November 14, 2020 Category: Epidemiology Source Type: research

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
This article aims at providing guidance on laboratory testing of classic anticoagulants and NOACs.
Source: Thrombosis Journal - November 4, 2014 Category: Hematology Authors: Jonathan DouxfilsAnne TamigniauBernard ChatelainCatherine GoffinetJean-Michel DognéFrançois Mullier Source Type: research